These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Tolman JA; Faulkner MA Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276 [TBL] [Abstract][Full Text] [Related]
4. The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms. Silverman RB J Med Chem; 2012 Jan; 55(2):567-75. PubMed ID: 22168767 [No Abstract] [Full Text] [Related]
5. Screening for vigabatrin (Sabril ®) retinal toxicity in children. Brodie SE Ophthalmic Genet; 2011 Nov; 32(4):193-5. PubMed ID: 21895515 [No Abstract] [Full Text] [Related]
6. [Visual field changes secondary to vigabatrin treatment]. Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of cyclopropane isosteres of the antiepilepsy drug vigabatrin and evaluation of their inhibition of GABA aminotransferase. Wang Z; Silverman RB J Enzyme Inhib Med Chem; 2004 Aug; 19(4):293-301. PubMed ID: 15558944 [TBL] [Abstract][Full Text] [Related]
8. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827 [TBL] [Abstract][Full Text] [Related]
9. A risk-benefit assessment of vigabatrin in the treatment of neurological disorders. Srinivasan J; Richens A Drug Saf; 1994 May; 10(5):395-405. PubMed ID: 8037889 [TBL] [Abstract][Full Text] [Related]
10. Vigabatrin: an antiepileptic drug with major benefits but significant adverse effects. Besag FM Curr Drug Saf; 2010 Jul; 5(3):188-90. PubMed ID: 20624131 [No Abstract] [Full Text] [Related]
12. Vigabatrin (Sabril) for epilepsy. Med Lett Drugs Ther; 2010 Feb; 52(1332):14-6; quiz 17. PubMed ID: 20208475 [No Abstract] [Full Text] [Related]
13. [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. Vogt H; Krämer G Schweiz Med Wochenschr; 1995 Jan; 125(4):125-32. PubMed ID: 7878401 [TBL] [Abstract][Full Text] [Related]
14. Vigabatrin: an effective antiepilepsy drug--balancing the risk of visual dysfunction. Krauss GL; Miller NR Ann Pharmacother; 1999 Dec; 33(12):1367-8. PubMed ID: 10630838 [No Abstract] [Full Text] [Related]
16. Visual field constriction on vigabatrin. Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799 [TBL] [Abstract][Full Text] [Related]
17. [Epilepsy and Sabril]. Depasse F Bull Soc Belge Ophtalmol; 2007; (304):33-40. PubMed ID: 17718226 [TBL] [Abstract][Full Text] [Related]
18. Vigabatrin. French JA Epilepsia; 1999; 40 Suppl 5():S11-6. PubMed ID: 10530689 [TBL] [Abstract][Full Text] [Related]
19. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects? Sorri I; Brigell MG; Mályusz M; Mahlamäki E; de Meynard C; Kälviäinen R Epilepsy Res; 2010 Nov; 92(1):48-53. PubMed ID: 20850272 [TBL] [Abstract][Full Text] [Related]
20. Vigabatrin and epilepsy: further lessons in early childhood. Parisi P; Bombardieri R; Curatolo P Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225 [No Abstract] [Full Text] [Related] [Next] [New Search]